NCT00369681View on ClinicalTrials.gov

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Lymphoma
Interventions
DRUG

Bleomycin

BIOLOGICAL

Rituximab

DRUG

Dacarbazine

DRUG

Doxorubicin

DRUG

Vinblastine

Trial Locations (4)

55905

Mayo Clinic Cancer Center, Rochester

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

52242-1009

Holden Comprehensive Cancer Center at University of Iowa, Iowa City

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00369681 - Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter